Although the clinical use of statins as anti‐cancer agents may be limited due to undefined dosage/schedule and potential toxicity at micromolar concentrations (Holstein et al, 2006), the development of agents targeting the MVA pathway should be further explored considering the key role of MVA pathway metabolites in oncogenic activities of YAP. The gene discussed is YAP1; the disease is cancer.